Squamous non-small cell lung cancersmall cell lung cancer has historically been one of oncology’s most punishing battlegrounds for novel combinations, and Akeso is walking into ASCO 2026’s Plenary Session on May 31 with overall survival data from HARMONi-6 — a Phase III trial that pits ivonescimab plus chemotherapy directly against tislelizumab plus chemotherapy in the first-line setting. That head-to-head design is the critical detail. This is not ivonescimab versus placebo or versus chemotherapy alone; it is a bispecific antibody engineered to co-block PD-1 and VEGF competing against an established PD-1 inhibitor on a survival endpoint. If the OS advantage holds, the mechanistic argument for dual PD-1/VEGF blockade in a single molecule moves from hypothesis to clinical fact.
The HARMONi-6 OS readout carries weight beyond lung cancer. Ivonescimab’s program spans at least four tumor types represented at this meeting — squamous NSCLC, SCLC after chemoimmunotherapy failure, metastatic colorectal cancer in a global Phase II, and neoadjuvant head and neck squamous cell carcinoma. That breadth is intentional. A positive Plenary result anchors the entire portfolio’s rationale: if simultaneous PD-1 and VEGF suppression through a single bispecific outperforms sequential or standalone checkpoint inhibition in a randomized Phase III, every downstream indication gets a stronger biological justification for continued investment.
The SCLC oral presentation deserves separate attention. Patients progressing after first-line chemoimmunotherapy represent one of oncology’s most treatment-resistant populations, with essentially no approved standard of care at second line. The combination of ivonescimab with liposomal irinotecan in that setting is a genuine clinical experiment — not a label-expansion exercise. Response rates and duration of response from that Phase II will tell investigators whether the VEGF arm of the bispecific is doing real work in a tumor type driven by angiogenesis and immune evasion simultaneously.
The single number that will define Akeso’s ASCO week is the hazard ratio from HARMONi-6’s OS analysis. A HR below 0.80 against an active PD-1 comparator in sq-NSCLC would constitute a statistically and clinically meaningful separation that Western regulators — and licensing partners — cannot dismiss as a China-only dataset, particularly with the mCRC Phase II already enrolling globally through sites like Valkyrie Clinical Trials in the U.S. Watch that HR above all else.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
